Genfit SA logo
Genfit SA GNFT

Annual report 2024
added 02-21-2026

report update icon

Genfit SA EPS Ratio 2011-2026 | GNFT

EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.

The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.

Calculated as:

EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]

EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.

A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.

EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.

Annual EPS Ratio Genfit SA

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011
- - - 1.51 -2.6 -1.76 -2.55 -1.79 - - - - - -

All numbers in EUR currency

Indicator range from annual reports

Maximum Minimum Average
1.51 -2.6 -1.44

References

  1. Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.

EPS Ratio of other stocks in the Biotechnology industry

Issuer EPS Ratio Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
-15.4 - 2.43 % $ 254 M germanyGermany
Aptorum Group Limited Aptorum Group Limited
APM
-0.78 $ 0.82 -3.48 % $ 4.47 M chinaChina
Rigel Pharmaceuticals Rigel Pharmaceuticals
RIGL
20.4 $ 33.23 -4.03 % $ 584 M usaUSA
Graybug Vision Graybug Vision
GRAY
-1.97 - -11.23 % $ 9.65 M usaUSA
I-Mab I-Mab
IMAB
-7.66 - - $ 866 M chinaChina
Acer Therapeutics Acer Therapeutics
ACER
-1.66 - 2.71 % $ 14 M usaUSA
Biophytis SA Biophytis SA
BPTS
-0.26 - -13.47 % $ 169 M franceFrance
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
-10.7 - -11.43 % $ 502 K usaUSA
Apellis Pharmaceuticals Apellis Pharmaceuticals
APLS
0.18 $ 20.15 -2.68 % $ 2.54 B usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
-0.49 $ 3.72 -2.75 % $ 1.11 B canadaCanada
Athersys Athersys
ATHX
-0.39 - 3.77 % $ 22.4 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
-31 - -18.52 % $ 27.3 M britainBritain
AVEO Pharmaceuticals AVEO Pharmaceuticals
AVEO
-1.63 - - $ 521 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
-3.68 $ 163.7 -1.61 % $ 8.14 B usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
-3.78 $ 64.66 -1.37 % $ 12.4 B usaUSA
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
-2.31 - -2.5 % $ 5.88 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
0.85 - -4.8 % $ 255 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
75.3 $ 8.52 -2.46 % $ 1.39 B britainBritain
Adverum Biotechnologies Adverum Biotechnologies
ADVM
-6.62 - - $ 86.2 M usaUSA
CymaBay Therapeutics CymaBay Therapeutics
CBAY
-0.99 - - $ 3.45 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
-2.23 - - $ 789 M usaUSA
Certara Certara
CERT
-0.01 $ 7.16 1.49 % $ 1.15 B usaUSA
ARCA biopharma ARCA biopharma
ABIO
-3.87 - 1052.0 % $ 415 M usaUSA
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
-1.42 - - $ 169 M usaUSA
Caladrius Biosciences Caladrius Biosciences
CLBS
-2.4 - -16.75 % $ 25.8 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
-1.73 - - $ 2.17 B usaUSA
Clovis Oncology Clovis Oncology
CLVS
-2.29 - -7.23 % $ 13 M usaUSA
Acorda Therapeutics Acorda Therapeutics
ACOR
-204 - -24.86 % $ 820 K usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
-2.84 - - $ 231 M usaUSA
Capricor Therapeutics Capricor Therapeutics
CAPR
-0.83 $ 25.91 -3.56 % $ 694 M usaUSA
Catalyst Pharmaceuticals Catalyst Pharmaceuticals
CPRX
1.75 $ 24.0 0.5 % $ 2.93 B usaUSA
Acasti Pharma Acasti Pharma
ACST
-0.79 - 4.01 % $ 150 M canadaCanada
Codexis Codexis
CDXS
-0.89 $ 0.99 -3.28 % $ 72.7 M usaUSA
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
-0.56 $ 17.75 -0.79 % $ 852 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
-0.81 - - $ 1.2 B usaUSA
CohBar CohBar
CWBR
-4.2 - -15.44 % $ 2.2 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCC
-504 - -5.98 % $ 34.1 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
-504 - -4.36 % $ 27 M usaUSA
Deciphera Pharmaceuticals Deciphera Pharmaceuticals
DCPH
-2.29 - - $ 2.18 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
-2.21 - - $ 867 M germanyGermany
Aeterna Zentaris Aeterna Zentaris
AEZS
-0.07 - 5.93 % $ 314 M canadaCanada
Denali Therapeutics Denali Therapeutics
DNLI
-2.57 $ 20.02 -4.67 % $ 3.29 B usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
-13.7 - -10.17 % $ 12.2 K usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
-24.9 - - $ 1.01 B usaUSA
Eton Pharmaceuticals Eton Pharmaceuticals
ETON
-0.04 $ 17.54 -3.36 % $ 450 M usaUSA
Entasis Therapeutics Holdings Entasis Therapeutics Holdings
ETTX
-1.09 - - $ 105 M usaUSA
Evofem Biosciences Evofem Biosciences
EVFM
10.4 - 7.55 % $ 38.1 M usaUSA